Lipoic acid - The drug of the future?

Pharmacological Reports

Volumn 57, Issue 5, 2005, Pages 570-577

  Bilska, Anna ^a   Włodek, Lidia ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Diabetes; Lipoic acid; Neurodegenerative diseases; Signal transduction; Tumors

Indexed keywords

ALPHA TOCOPHEROL; AMYLOID PRECURSOR PROTEIN; ANTIOXIDANT; CYTOKINE RECEPTOR; DIHYDROLIPOATE; DOPAMINE; GLUTATHIONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; INTERLEUKIN 1BETA; LEVODOPA; PLACEBO; REACTIVE OXYGEN METABOLITE; SELENIUM; SILYMARIN; STREPTOZOCIN; THIOCTIC ACID; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR RECEPTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALZHEIMER DISEASE; ANTIOXIDANT ACTIVITY; CANCER INHIBITION; CATARACT; CELL DIFFERENTIATION; CELL GROWTH; CLINICAL STUDY; CLINICAL TRIAL; CONCENTRATION RESPONSE; DEGENERATIVE DISEASE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; EXPERIMENTAL STUDY; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PANCREAS ISLET BETA CELL; PARKINSON DISEASE; REVIEW; SIGNAL TRANSDUCTION; STREPTOZOCIN DIABETES; STRUCTURE ANALYSIS;

EID: 33644664987     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. Antkiewicz-Michaluk L: Perspectives in antiparkinsonian medicines research. In: Neuropsychopharmacology. Today and Tomorrow (Polish). Ed. Bijak M, Lasoń W, Kraków, 2000, 235-262.
2. Antkiewicz-Michaluk L, Krygowska-Wajs A, Michaluk J, Romańska I, Szczudlik A, Vetulani J: Plasticity of extrapyramidal dopamine system in Parkinson's disease - post mortem study. Neurosci Res Commun, 1999, 25, 97-109.
3. 2 with intracellular glutathione enhancement of its antiproliferative activity by glutathione depletion. Cancer Res, 1990, 50, 1879-1885.
4. Beitner H: Randomized, placebo-controlled, double blind study on the clinical efficacy of a cream containing 5% α-lipoic acid related to photoageing of facial skin. Br J Dermatol, 2003, 149, 841-849.
5. Berkson BM: A conservative triple antioxidant approach to the treatment of hepatitis C. Combination of α-lipoic acid (thioctic acid), silymarin, and selenium: three case histories. Med Klin, 1999, 94, Suppl 3, 84-89.
6. Butterfield DA, Hensley K, Harris M, Mattson M, Carney J: β-Amyloid peptide free radical fragments initiate synaptosomal lipoperoxidation in a sequence-specific fashion: implications to Alzheimer's disease. Biochem Biophys Res Commun, 1994, 200, 710-715.
7. Buttke TM, Sandstrom PA: Redox regulation of programmed cell death in lymphocytes. Free Radic Res, 1995, 22, 389-397.
8. Deneke SM: Thiol-based antioxidants. Curr Top Cell Regul, 2000, 369, 151-180.
9. Dovinova I, Novotny L, Rauko P, Kvasnicka P: Combined effect of lipoic acid and doxorubicyn in murine leukemia. Neoplasma, 1999, 46, 237-241.
10. Faust A, Burkart V, Ulrich H, Weischer CH, Kolb H: Effect of lipoic acid on cyclophosphamide-induced diabetes and insulitis in non-obese diabetic mice. Int J Immunopharmacol, 1994, 16, 61-66.
11. Hager K, Marahrens A, Kenklies M, Riederer P, Munch G: α-Lipoic acid as a new treatment option for Alzheimer type dementia. Arch Gerontol Geriatr, 2001, 32, 275-282.
12. Haugaard N: Cellular mechanisms of oxygen toxicity. Physiol Rev, 1968, 48, 311-373.
13. Horowitz PM, Butler M, McClure GDJr: Reducing sugars can induce the oxidative inactivation of rhodanese. J Biol Chem, 1992, 267, 23596-23600.
14. Huang ZZ, Chen C, Zeng Z, Yang H, Oh J, Chen L, Lu SC: Mechanism and significance of increased glutathione level in human hepatocellular carcinoma and liver regeneration. FASEB J, 2001, 15, 19-21.
15. Jacob S, Henriksen EJ, Tritschler HJ, Augustin HJ, Dietze GJ: Improvement of insulin-stimulated glucose-disposal in type 2 diabetes after repeated parenteral administration of thioctic acid. Exp Clin Endocrinol Diabetes, 1996, 104, 284-288.
16. Jacob S, Ruus P, Hermann R, Tritschler HJ, Maerker E, Renn W, Augustin HJ et al.: Oral administration of RAC-alpha-lipoic acid modulates insulin sensitivity in patients with type-2 diabetes mellitus: a placebo-controlled pilot trial. Free Radic Biol Med, 1999, 27, 309-314.
17. Jacob S, Streeper RS, Fogt DL, Hokama JY, Tritschler HJ, Dietze GJ, Henriksen EJ: The antioxidant α-lipoic acid enhances insulin-stimulated glucose metabolism in insulin-resistant rat skeletal muscle. Diabetes, 1996, 45, 1024-1029.
18. Jenner P, Brin MF: Levodopa neurotoxicity: experimental studies versus clinical relevance. Neurology, 1998, 50, 39-43.
19. Kahler W, Kuklińiski B, Ruhlmann C, Plotz C: Diabetes mellitus - a free radical-associated disease. Results of adjuvant antioxidant supplementation (German). Z Gesamte Inn Med, 1993, 48, 223-232.
20. Keyse SM, Tyrrel RM: Heme oxygenase is the major 32-kDa stress protein induced in human skin fibroblasts by UVA radiation, hydrogen peroxide, and sodium arsenite. Proc Natl Acad Sci USA, 1989, 86, 99-103.
21. Kilic F, Handelman GJ, Serbinova E, Packer L, Trevithick JR: Modelling cortical cataractogenesis 17: in vitro effect of α-lipoic acid on glucose-induced lens membrane damage, a model of diabetic cataractogenesis. Biochem Mol Biol Int, 1995, 37, 361-370.
22. Kowalska A: Genetic basis of neurodegeneration in familial Alzheimer's disease. Pol J Pharmacol, 2004, 56, 171-178.
23. Maitra I, Serbinova E, Trischler H, Packer L: α-Lipoic acid prevents buthionine sulfoximine-induced cataract formation in newborn rats. Free Radic Biol Med, 1995, 18, 823-829.
24. 2 and antioxidants have opposite effects on activation of NF-kappa B and AP-1 in intact cells: AP-1 as secondary antioxidant-responsive factor. EMBO J, 1993, 12, 2005-2015.
25. Montironi R, Mazzucchelli R, Stramazzotti D, Pomante R, Thompson D, Barlel PH: Expression of pi-class glutathione S-transferase: two populations of high grade prostatic intraepithelial neoplasia with different relations to carcinoma. Mol Pathol, 2000, 53, 122-128.
26. Pace GW, Leaf CD: The role of oxidative stress in HIV disease. Free Radic Biol Med, 1995, 9, 523-528.
27. Packer L: α-Lipoic acid: a metabolic antioxidant which regulates NF-kappa B signal transduction and protects oxidative injury. Drug Metab Rev, 1998, 30, 245-275.
28. Packer L, Tritschler HJ, Wessel K: Neuroprotection by the metabolic antioxidant alpha-lipoic acid. Free Radic Biol Med, 1997, 22, 359-378.
29. Packer L, Witt EH, Tritschler HJ: α-Lipoic acid as a biological antioxidant. Free Radic Biol Med, 1995, 19, 227-250.
30. Panigrahi M, Sadguna Y, Shivakumar BR, Kolluri SV, Roy S, Packer L, Ravindranath V: α-Lipoic acid protects against reperfusion injury following cerebral ischemia in rats. Brain Res, 1996, 717, 184-188.
31. Patel MS, Vettakkorumakankav NN: Lipoic acid-requiring proteins: recent advances. In: Biothiols in Health and Disease. Ed. Packer L, Cadenas E, Marcel Dekker Inc., New York, 1995, 373-388.
32. Pauling L: Orthomolecular psychiatry. Varying the concentrations of substances normally present in the human body may control mental disease. Science, 1968, 160, 265-271.
33. Prehn JH, Karkoutly C, Nuglisch J, Peruche B, Krieglstein J: Dihydrolipoate reduces neuronal injury after cerebral ischemia. Cereb Blood Flow Metab, 1992, 12, 78-87.
34. Reed LJ, DeBusk BG, Gansalus IC, Homberger JrCS: Crystalline α-lipoic acid: a catalytic agent associated with pyruvate dehydrogenase. Science, 1951, 114, 93-94.
35. Roy S. Packer L: Redox regulation of cell functions by α-lipoate. Biofactors, 1998, 8, 17-21.
36. Schleicher E, Wagner E, Nehrlich AG: Increased accumulation of the glyoxidation product N-epsilon-(carboxy-methyl)-lysine in human tissues in diabetes and aging. J Clin Invest, 1997, 99, 457-468.
37. Seaton TA, Jenner P, Marsden CD: Thioctic acid does not restore glutathione levels or protect against the potentiation of 6-hydroxydopamine toxicity induced by glutathione depletion in rat brain. J Neural Transm, 1996, 103, 315-329.
38. Spencer JP, Jenner P, Daniel SE, Lees AJ, Marsden DC, Halliwell B: Conjugates of catecholamines with cysteine and GSH in Parkinson's disease: possible mechanisms of formation involving reactive oxygen species. J Neurochem, 1998, 7, 2112-2122.
39. Strodter D, Lehmann E, Lehmann U, Tritschler HJ, Bretzel RG, Federlin K: The influence of thioctic acid on metabolism and function of the diabetic heart. Diabetes Res Clin Pract, 1995, 29, 19-26.
40. Suzuki YJ, Tsuchiya M, Packer L: Lipoate prevents glucose-induced protein modifications. Free Radic Res Commun, 1992, 17, 211-217.
41. Vinik AI, Park TS, Stansberry KB, Pittenger GL: Diabetic neuropathies. Diabetologia, 2000, 43, 957-973.
42. Wolz P, Krieglstein J: Neuroprotective effects of alpha-lipoic acid and its enantiomers demonstrated in rodent models of focal cerebral ischemia. Neuropharmacology, 1996, 35, 369-375.
43. Ziegler D, Hanefeld M, Ruhnau KJ, Meissner HP, Lobisch M, Schutte K, Gries FA: Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant α-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study). Diabetologia, 1995, 38, 1425-1433.
44. Ziegler D, Nowak H, Kempler P, Vargha P, Low PA: Treatment of symptomatic diabetic polyneuropathy with the antioxidant α-lipoic acid: a meta-analysis. Diabet Med, 2004, 21, 114-121.